Gender Differences in the Application of Spanish Criteria for Initiation of Enzyme Replacement Therapy for Fabry Disease in the Fabry Outcome Survey
Barba Romero, Miguel Ángel (Universidad de Castilla-La Mancha. Departamento de Ciencias Médicas)
Pintos-Morell, Guillem (Universitat Autònoma de Barcelona. Departament de Pediatria, Obstetrícia i Ginecologia i Medicina Preventiva i Salut Pública)

Date:	2016
Abstract:	Both male/female patients with Fabry disease (FD) may receive enzyme replacement therapy (ERT). Previously published analyses of the Fabry Outcome Survey (FOS; Shire-sponsored) database suggested gender differences in timing of ERT initiation. We assessed alignment of criteria for ERT initiation in the Spanish adult population included in FOS with recommendations of a Spanish national consensus. This retrospective analysis examined baseline clinical data of 88 adults (49 females) enrolled in the FOS database up to August 2014. Thirty-five (39. 8%) patients were not receiving ERT: five (12. 8%) males and 30 (61. 2%) females. Baseline disease severity on the FOS-derived Mainz Severity Score Index was lower in untreated males (median (interquartile range), 0. 0 (0. 0-1. 0)) than treated males (TM; 15. 0 (7. 5-26. 5)), and was similar in untreated and treated females. The percentage of untreated females with at least one criterion for treatment initiation was 76. 7% versus 100. 0% of treated females (p = 0. 0340) and 97. 1% (p = 0. 0210) of TM. In discordance with Spanish consensus recommendations, a substantial number of females with evidence of FD who might benefit from ERT have not yet initiated treatment. These results suggest unequal gender perceptions with respect to ERT initiation in Spain.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Agalsidase alfa ; Enzyme replacement therapy ; Fabry disease ; Fabry Outcome Survey (FOS) ; Gender differences ; Spain ; Women
Published in:	International journal of molecular sciences, Vol. 17 Núm. 12 (November 2016) , ISSN 1422-0067

DOI: 10.3390/ijms17121965
PMID: 27886142

11 p, 1.5 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles